Related Experiment Videos
N-oxides as hypoxia selective cytotoxins
1Departamento de Química Orgánica, Facultad de Química y Facultad de Ciencias, Universidad de la República, Avda Gral Flores 2124 CC 1157, 11800 Montevideo Uruguay. hcerecet@bilbo.edu.uy
Abstract:
N-oxide-containing compounds have been developed as prodrugs that are selectively bioactivated in the hypoxic cells in tumors. This selectivity is based on the net reduction of the N-oxide moiety in the absence of oxygen, in a one or two-electron process, by reductive enzymes. A wide range of N-oxides have been studied and some of them are currently in clinical use. This review covers the principal families of compounds under study and in clinical trials.
Insights
N-oxide prodrugs are selectively activated in hypoxic tumor cells via reductive enzymes. This review details N-oxide compounds currently in clinical trials for cancer therapy.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Hypoxic tumor microenvironments present unique targets for cancer therapy.
- N-oxide-containing compounds serve as prodrugs, requiring reductive bioactivation.
- Selective activation in hypoxic cells offers a strategy to minimize systemic toxicity.
Purpose of the Study:
- To review the principal families of N-oxide compounds.
- To discuss N-oxides currently under study and in clinical trials.
- To highlight the mechanism of selective bioactivation in hypoxic tumor cells.
Main Methods:
- Literature review of N-oxide prodrugs.
- Analysis of bioactivation pathways involving reductive enzymes.
- Survey of compounds in preclinical and clinical development.
Main Results:
- N-oxide moiety reduction is a key bioactivation step.
- One- and two-electron reduction processes are involved.
- Several N-oxide families show promise and are in clinical use.
Conclusions:
- N-oxide prodrugs demonstrate significant potential for targeted cancer therapy.
- The selective bioactivation mechanism in hypoxic tumors is well-established.
- Ongoing research and clinical trials are advancing N-oxide-based treatments.